1. Home
  2. |Insights
  3. |COVID-19 Health Care Funding, Regulatory Waivers, and the False Claims Act: Protecting Your Business Today from Agency Enforcement and Whistle Blower Actions Tomorrow

COVID-19 Health Care Funding, Regulatory Waivers, and the False Claims Act: Protecting Your Business Today from Agency Enforcement and Whistle Blower Actions Tomorrow

Webinar | 04.30.20, 11:00 AM EDT - 12:00 PM EDT

Register

Click here to access a PDF of the slides.

To combat the COVID-19 pandemic, Congress has passed the CARES Act as well as other stimulus legislation authorizing many different funding streams for which a variety of health care entities are eligible, e.g., through the Public Health and Social Services Emergency Fund and the Paycheck Protection Program. Though these funds provide necessary assistance throughout the industry, they also are subject to a number of terms and conditions and reporting obligations, will be a target of audits, and come with substantial False Claims Act (FCA) enforcement risk. In addition to funding, HHS has granted several Section 1135 waivers, such as with respect to the Stark Law, other regulatory flexibilities, and modifications to reimbursement. These changes offer providers and suppliers more latitude given the challenges posed by the pandemic, but compliance with the new guidance is imperative to mitigate FCA enforcement risk and whistleblower actions in the future.   


Join us on Thursday, April 30, 2020 from 2:00 - 3:00 pm EDT for a webinar discussing these risks as well as strategies and best practices you can implement today to mitigate potential FCA actions and other enforcement in the future.


Contact

Participants

Insights

Webinar | 10.16.25

The Artificial Intelligence Agenda from Capitol Hill to State Capitals: Where We Are and Where We Are (Probably) Going

The landscape of AI governance and regulation is shifting. Following the release of the White House’s “America’s AI Action Plan” in July 2025 and the President’s signing of related Executive Orders, the White House has emphasized (at least rhetorically) a preference for innovation, adoption, and deregulation. But that does not tell the entire story. The Administration remains committed to exercising a heavy hand in AI, including by banning the U.S. government’s procurement of so-called “woke AI,” intervening in the development of data centers and the export of the AI technology stack, imposing an export fee for certain semiconductors to China, and assuming a stake in a U.S. semiconductor company. State legislatures are also racing to implement their own regulations, particularly around AI’s use in critical areas, such as healthcare, labor and employment, and data privacy. The many sources of regulation raise the specter of a fragmented compliance environment for businesses. This webinar will delve into the Administration’s AI strategy, going beyond the headlines to analyze:...

View All Insights